Updated:
Sorrento Therapeutics
Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable...
Sorrento Therapeutics
Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19
General information
Firm type
Publicly Traded Biopharmaceutical
Location
Region
North America
Country
United States
City
San Diego
Corporate office
9380 Judicial Drive, San Diego, CA 92121, United States
Additional offices
Princeton · Nashville · Wilton · Los Altos · Paris · Singapore
Sector focus
Frequently asked questions
Who leads investment and R&D decisions at Sorrento Therapeutics?
Dr. Henry Ji, the founder, serves as President and CEO. The company's scientific direction is guided by an internal team of researchers and clinical development specialists, with board oversight for strategic decisions.
How is Sorrento Therapeutics structured — as a single entity or with subsidiaries?
Sorrento operates multiple subsidiaries, including Scilex Pharmaceuticals (pain management), a CAR-T cell therapy unit, and a diagnostics division. These are wholly owned and integrated into the parent company's development and manufacturing pipeline.
Does Sorrento partner with external firms for development or manufacturing?
Yes, Sorrento has formed partnerships with major pharmaceutical distributors and contract manufacturing organizations to scale production and distribution, particularly for its COVID-19 diagnostics and pain therapy candidates.
What investment stages does Sorrento Therapeutics target?
Sorrento is a development-stage biopharmaceutical company, not a family office or asset manager. Its capital deployment focuses on internal R&D, clinical trials, and manufacturing infrastructure, not external portfolio investing.
Where does the underlying wealth for Sorrento's operations come from?
As a publicly traded company, Sorrento raises capital through equity offerings, debt, and partnership/licensing deals. It does not disclose a single private wealth source or endowment backing.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: